Brief: Medincell: Product Portfolio Progresses Well Amid COVID-19 Pandemic
23/04/2020 07:11
April 23 (Reuters) - MEDINCELL SA MEDCL.PA :
* MEDINCELL: ADAPT AND OVERCOME IN RESPONSE TO THE COVID-19
CRISIS
* SOLID FINANCIAL VISIBILITY
* PRODUCT PORTFOLIO PROGRESSES WELL
Source text for Eikon: ID:nBw2fH1T0a
Further company coverage: MEDCL.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris